Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.

But more detail is awaited, especially on toxicity.

The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.

The ESMO regular abstract lift reveals first human datasets for several projects.

The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.